Logo of IZERVAY My Way

IZERVAY My WaySM is a patient support program customized to your unique patient-access needs.

Benefits
Investigations

Affordability
Options*

Prior Authorization
Support†

Patient Assistance
Program*

Appeals/Denials
Support†

Product
Replacement*

*Subject to eligibility requirements. Void where prohibited by law. See complete terms and conditions available at IZERVAYecp.com/PatientSupport, or reach out to your Access Coordinator.

†The healthcare provider remains responsible for populating all clinical documentation.

Initiation

76%1‡

of surveyed customers found initiation for IZERVAY easy

Speed

0.5 days1§

average benefit investigation turnaround time

Programs

80%1‡

were highly satisfied with IZERVAY My Way patient support services

‡Based on Awareness, Trial, and Usage (ATU) survey of 50 customers, October 2024.

§Based on benefits investigations conducted by IZERVAY My Way, February 2025.

Get started today. Complete IZERVAY My WaySM enrollment in any of the following ways:

Enroll on the IZERVAY My Way Portal

The IZERVAY My WaySM portal is your place for all access and affordability solutions for your patients prescribed IZERVAYTM.

OR

Download the enrollment form and submit it via email or fax
Enrollment Form
Download Enrollment Form
Email
Support@IZERVAYMyWay.com
Fax
1-833-C5MYWAY (1-833-256-9929)

If you need assistance, please don’t hesitate to contact our team for live support. Phone: 1-888-C5MYWAY (1-888-256-9929) 8 AM to 8 PM ET Monday – Friday

Once your patient is enrolled, a dedicated Access Coordinator will reach out to you to help your patient get started.

Our broad distribution network is designed to accelerate access.

Authorized specialty distributor
Product order number
Contact information
Website
Besse Medical
Product order number
10282423
Phone: 800-543-2111
Fax: 800-543-8695
besse.com
BioCare
Product order number
10000910
Phone: 800-304-3064
biocare.com
Cardinal Health Specialty Distribution
Product order number
5877782
Phone: 855-855-0708
Fax: 614-553-6301
cardinalhealth.com
CuraScript Specialty Distribution
Product order number
478067
Phone: 877-599-7748
Fax: 800-862-6208
curascript.com
McKesson Plasma and Biologics, LLC
Product order number
2996445
Phone: 877-625-2566
Fax: 888-752-7626
mckesson.com
McKesson Specialty Care Distribution
Product order number
5018908
Phone: 800-482-6700
Fax: 800-800-5673
mckesson.com
Metro Medical
Product order number
828290
Phone: 800-768-2002
metromedicalorder.com

IZERVAY is also available through a broad open network of specialty pharmacies if mandated by a patient’s health plan. Be sure to contact the specialty pharmacy to confirm availability.

Discover affordability options for your patients across insurance types.

Commercial
Commercial copay program
$0
Eligible commercial patients may pay as little as $0 for their treatment.
Maximum benefit applies. Click here to view complete terms and conditions.

Visit IZERVAYCommercialCopay.com for self-service, copay-only support.

IZERVAYCommercialCopay.com
OR

Enroll your patient into our IZERVAY My WaySM program for copay and other offerings with support from an Access Coordinator.

IZERVAY My WaySM
Underinsured/uninsured
Patient assistance program

Financially eligible patients may be able to receive IZERVAY at no cost.

Click here to view terms and conditions.

Enroll your patient into our IZERVAY My WaySM program for copay and other offerings with support from an Access Coordinator.

IZERVAY My WaySM

Download the Billing and Coding Guide for helpful information on coding and billing for IZERVAY

Billing and Coding Guide

Downloadable Resources

Resources are available for you and your patients throughout their treatment experience.

Thumbnail of FDA approval letter (February 2025)
FDA Approval Letter (February 2025)
Download
Thumbnail of Distribution and Acquisition Flashcard
Distribution and Acquisition Flashcard
Download
Thumbnail of IZERVAY My Way Enrollment Form
IZERVAY My WaySM Enrollment Form
Download
Thumbnail of Patient Support Program Flashcard
Patient Support Program Flashcard
Download
Thumbnail of Commercial Copay Flashcard
Commercial Copay Flashcard
Download
Thumbnail of Sample Letter of Medical Necessity
Sample Letter of Medical Necessity
Download
Thumbnail of Sample Letter of Appeal
Sample Letter of Appeal
Download
Thumbnail of Sample Letter of Reauthorization
Sample Letter of Reauthorization
Download
Icon of an envelope with a check mark
FDA Approval Letter (August 2023)
Download
Thumbnail of Sample Letter of Coverage Delays
Sample Letter of Coverage Delays
Download
Thumbnail of Billing and Coding Guide
Billing and Coding Guide
Download

Thumbnail of Patient Brochure
Patient Brochure
Download
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Over 24 months, the rate of neovascular (wet) AMD or choroidal neovascularization in the GATHER2 trial was 12% in the IZERVAY group and 9% in the sham group. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.